Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts, Mark A. Socinski, Paul Mitchell(Austin Hospital), Nick Thatcher(The Christie Hospital), Libor Havel, Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Sergiusz Nawrocki(University of Warmia and Mazury in Olsztyn), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Lionel Bosquée, José Trigo(Hospital Clínico Universitario Virgen de la Victoria), Alexander I. Spira(Virginia Cancer Specialists), Lise Tremblay(Institut Universitaire de Cardiologie et de Pneumologie de Québec), Jan Nyman(Sahlgrenska University Hospital), Rodryg Ramlau(Poznan University of Medical Sciences), Gun Wickart-Johansson(Karolinska University Hospital), Peter Ellis(Juravinski Cancer Centre), Oleg Gladkov(Chelyabinsk Regional Clinical Oncology Center), José Rodrigues Pereira, Wilfried Eberhardt(University of Duisburg-Essen), Christoph Helwig(Merck (Germany)), Andreas Schröder(Merck (Germany)), Frances A. Shepherd(University Health Network)
Cited by 523Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis